舒利迭以及金水宝胶囊联合治疗慢性阻塞性肺疾病的有效性

Effectiveness by Seretide and Jinshuibao capsules in combined treatment of chronic obstructive pulmonary disease

目的探究沙美特罗替卡松粉吸入剂(舒利迭)以及金水宝胶囊联合治疗慢性阻塞性肺疾病的有效性,对慢性阻塞性肺疾病的治疗提供建设性意见。方法 96例慢性阻塞性肺疾病患者,依照患者治疗的先后顺序分成参照组和联合组,各48例。参照组患者给予常规药物舒利迭治疗,联合组患者在参照组的基础上加用金水宝胶囊治疗。比较两组患者用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC指标变化情况及治疗效果。结果治疗后,联合组患者FEV1/FVC、FEV1、FVC分别为(94.46±8.11)%、(1.89±0.55)L、(2.76±0.29)L,均优于参照组患者的(71.47±10.96)%、(1.52±0.57)L、(2.44±0.81)L,差异具有统计学意义(P<0.05)。联合组患者中治疗显效36例(75.00%),好转10例(20.83%),无效2例(4.17%),治疗总有效率为95.83%;参照组患者中治疗显效22例(45.83%),好转12例(25.00%),无效14例(29.17%),治疗总有效率为70.83%;联合组患者治疗总有效率明显高于参照组,差异具有统计学意义(P<0.05)。结论舒利迭联合金水宝胶囊应用于慢性阻塞性肺疾病患者的治疗中,可有效改善患者的肺功能,其临床治疗效果佳,临床推广价值显著。

Objective To investigate effectiveness by salmeterol xinafoate and fluticasone propionate powder for inhalation（Seretide） and Jinshuibao capsules in combined treatment of chronic obstructive pulmonary disease, and to provide constructive suggestion for treatment of chronic obstructive pulmonary disease. Methods A total of 96 patients with chronic obstructive pulmonary disease were divided by their admission order into control group and combined group, with 48 cases in each group. The control group received conventional drug therapy by Seretide, and the combined group received additional Jinshuibao capsules for treatment to therapy in the control group. Comparison was made on changes in forced vital capacity（FVC）, forced expiratory volume in 1 second（FEV1）, FEV1/FVC and curative effects between the two groups. Results After treatment, the combined group had FEV1/FVC, FEV1 and FVC respectively as（94.46±8.11）,（1.89±0.55） L and（2.76±0.29） L, which were all better than（71.47±10.96）,（1.52±0.57） L and（2.44±0.81） L in the control group, and their difference had statistical significance（P0.05）. The combined group had 36 excellent cases（75.00%）, 10 improved cases（20.83%） and 2 ineffective cases（4.17%）, with total effective rate in treatment as 95.83%. The control group had 22 excellent cases（45.83%）, 12 improved cases（25.00%） and 14 ineffective cases（29.17%）, with total effective rate in treatment as 70.83%. The combined group had obviously higher total effective rate in treatment than the control group, and their difference had statistical significance（P0.05）. Conclusion Combination of Seretide and Jinshuibao capsules in the treatment of chronic obstructive pulmonary disease can effectively improve pulmonary function in patients, along with excellent clinical effect. This method contains remarkable value for clinical promotion.